Xintian Pharma released its performance for the first three quarters, with a net profit attributable to the parent company of 16.1809 million yuan, a year-on-year decrease of 73.47%
According to the Zhitong Finance APP, Xintian Pharma released its third-quarter report for 2025. In the first three quarters, the company achieved operating revenue of 559 million yuan, a year-on-year decrease of 15.47%. The net profit attributable to shareholders of the listed company was 16.1809 million yuan, a year-on-year decrease of 73.47%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 13.5545 million yuan, a year-on-year decrease of 67.93%
According to the Zhitong Finance APP, Xintian Pharma (002873.SZ) released its third-quarter report for 2025. In the first three quarters, the company achieved an operating income of 559 million yuan, a year-on-year decrease of 15.47%. The net profit attributable to shareholders of the listed company was 16.1809 million yuan, a year-on-year decrease of 73.47%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 13.5545 million yuan, a year-on-year decrease of 67.93%
